CurrentNeighborhood Health Plan of Rhode IslandPolicy SCIG 2043-A SGM P2023a

Subcutaneous Immune Globulin (SCIG) therapy coverage

Defines coverage, indications, documentation and prior authorization criteria for subcutaneous immune globulin products (Hizentra, HyQvia, Cutaquig, Cuvitru, Xembify) for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicySubcutaneous Immune Globulin (SCIG) therapy coverage

Policy CodePolicy SCIG 2043-A SGM P2023a

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization with indication-specific documentation and meet initial or reauthorization criteria as listed.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5named FDA-approved SCIG products listed

45+compendial/other listed indications

1–6minitial authorization range

6–12mreauthorization duration

20+distinct indications listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria and indication-specific authorization

inv-25: Churg-Strauss Syndrome (EGPA)

Authorization of 6 months may be granted for severe, active Churg-Strauss syndrome (Eosinophilic Granulomatosis with Polyangiitis) as adjunctive therapy when the following are met:

ALL of the following

Diagnosis of Churg-Strauss syndrome (Eosinophilic Granulomatosis with Polyangiitis) confirmed by appropriate clinical criteria, including asthma, eosinophilia, and systemic vasculitis manifestations (e.g., neuropathy, pulmonary infiltrates, renal involvement, or sinusitis).
Member has severe or active disease with organ- or life-threatening manifestations or rapidly progressive symptoms.
Member has failed to respond to, is intolerant of, or has a contraindication to first-line therapies (e.g., systemic corticosteroids and conventional immunosuppressive agents such as cyclophosphamide, azathioprine, or methotrexate).
IG therapy is being used as adjunctive treatment in conjunction with appropriate baseline immunosuppressive management and under the supervision of a specialist (e.g., rheumatologist, pulmonologist, or immunologist).

Coding and clinical thresholds

No codes listed in this sectionmixed

No codes listed

IgG trough / pretreatment IgG threshold reference values

SCID / congenital agammaglobulinemia pretreatment IgG< 200 mg/dL

CVID / hypogammaglobulinemia / CLL pretreatment IgG< 500 mg/dL or ≥ 2 standard deviations below mean for age

Pediatric prophylaxis / post-transplant / secondary immunodeficiency IgG< 400 mg/dL

Age threshold for FDA-indicated replacement therapy

FDA age threshold for SCIG replacement therapyAge ≥ 2 years for listed SCIG products (Cutaquig, Cuvitru, Hizentra, HyQvia, Xembify)

Hizentra CIDP indication ageAdults (CIDP maintenance indication applies to adults)

Prior authorization, documentation, and denial risks

Prior Authorization

Prior authorization required

Prior authorization is required for all indications of subcutaneous immune globulin (SCIG). Requests must include indication-specific documentation described below. Authorization durations vary by indication (see criteria).

Prior authorization required for SCIG per plan policy.
Authorization duration is indication-dependent (see clinical criteria).

Prior Authorization

Indication-based prior authorization and durations

Initial and continuation authorization durations and criteria are indication-based. Submit documentation supporting the specific diagnosis and the applicable initial or reauthorization criteria (e.g., laboratory data, diagnostic testing, treatment history).

Initial and reauthorization timeframes: examples include 1 month, 3 months, 6 months, or 12 months depending on diagnosis and response.
Reauthorization requires meeting the condition-specific continuation criteria in section IV and the diagnosis-specific reauthorization points in section III.

Clinical background and scope

Subcutaneous immune globulin (SCIG) products are used as both replacement therapy for primary humoral immunodeficiency and as immunomodulatory or prophylactic therapy across a broad range of autoimmune, neurologic, infectious prophylaxis, transplant-related, and other conditions. The policy lists specific SCIG indications including dermatomyositis, polymyositis, myasthenia gravis, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, fetal/neonatal alloimmune thrombocytopenia, parvovirus B19-induced pure red cell aplasia, stiff-person syndrome, immune checkpoint inhibitor–related toxicities, and numerous transplant and infection-prophylaxis scenarios. For vaccine-response–based indications, Appendix A clarifies that impaired pneumococcal polysaccharide vaccine response applies to members aged 2 years and older and excludes therapy initiated in the hospital setting.

Key definitions and diagnostic confirmation

Hizentra maintenance therapy limitation

Hizentra CIDP maintenance study durationSystematically studied for 6 months with additional 12-month follow-up

Implication for therapy beyond studied periodMaintenance therapy beyond studied periods should be individualized based on patient response and need

RelevanceLimits generalizability of long-term maintenance; informs documentation and clinical decision-making

Diagnostic confirmation for LEMS

LEMS diagnostic confirmation methodsNeurophysiology studies (e.g., electromyography) or a positive anti-P/Q type voltage-gated calcium channel antibody test

Prerequisite prior therapiesAnticholinesterases and amifampridine should have been tried and were unsuccessful or not tolerated

Policy revision history

2024-01-01policy_updateLatest

Policy document version SCIG 2043-A SGM P2023a published/updated with referenced package inserts and literature; includes HyQvia package insert (Jan 2024) and multiple product references.

2023-11-01reference_update

Hizentra package insert (April 2023) and Cuvitru package insert (March 2023) added to references for product-specific information.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicySubcutaneous Immune Globulin (SCIG) therapy coverage

Policy CodePolicy SCIG 2043-A SGM P2023a

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization with indication-specific documentation and meet initial or reauthorization criteria as listed.

SourceLink

On This Page

General pediatric noteProduct approvals uniformly specify pediatric patients 2 years of age and older

ITP platelet counts (adult and pediatric thresholds)

Adult newly diagnosed ITP platelet count< 30,000/mcL (or < 50,000/mcL with significant bleeding or high bleeding risk)

Pediatric newly diagnosed ITP criteriaSignificant mucosal or moderate/severe bleeding, or high bleeding risk, or need for rapid platelet increase

Chronic/persistent and refractory ITP adults< 30,000/mcL or < 50,000/mcL with bleeding/high risk; relapse after prior response or failure/intolerance to corticosteroid or anti-D therapy

Total IgG threshold for HLH/MAS

Total IgG threshold for HLH / MASTotal IgG < 400 mg/dL or two standard deviations below the mean for age

Authorization durationAuthorization of 6 months may be granted when threshold met

ContextUsed for treatment of hypogammaglobulinemia in HLH/MAS

Pediatric IgG threshold for HIV-associated thrombocytopenia

Pediatric HIV-associated thrombocytopenia IgG thresholdIgG < 400 mg/dL

Additional pediatric criteriaPlus one of: ≥2 bacterial infections in 1 year despite prophylaxis; failed to form antibodies to common antigens; lives in high-measles-prevalence region after 2 MMR doses; measles exposure request; chronic bronchiectasis; T4 ≥ 200/mm3

Initial authorization duration6 months when criteria met

Adult platelet threshold for HIV-associated thrombocytopenia

Adult platelet threshold for HIV-associated thrombocytopeniaPlatelet count < 20,000/mcL

Additional adult criterionSignificant bleeding and failure of RhIG in Rh-positive patients

Initial authorization duration6 months when criteria met

IgG < 400 mg/dL repeated threshold

Repeated IgG threshold used across several indicationsIgG < 400 mg/dL

Applies toPediatric HIV prophylaxis, BMT/HSCT post-transplant, CAR-T related hypogammaglobulinemia, and secondary immunosuppression contexts

Authorization duration when metTypically 6 months

Platelet count < 20,000/mcL

Critical platelet count for severe bleeding riskPlatelet count < 20,000/mcL

Use casesSpecified for adult HIV-associated thrombocytopenia; denotes significant bleeding risk requirement for some authorizations

Authorization duration6 months when criteria met (adult HIV-associated thrombocytopenia)

Measles exposure window (<6 days)

Measles (rubeola) postexposure windowExposure occurred less than 6 days previously

IndicationPostexposure prophylaxis to prevent or modify measles in susceptible members

Authorization duration1 month for postexposure prophylaxis

Prior Authorization

Continuation authorization criteria

Continuation (re-authorization) will be granted only when condition-specific reauthorization criteria are met. For primary immunodeficiency examples, reauthorization criteria include reduced infection frequency and periodic IgG trough monitoring; for neurologic and autoimmune conditions, documentation of clinical improvement or stability is required.

Primary immunodeficiency: reduction in bacterial infections AND yearly IgG trough levels maintained at/above lower range for age, or prescriber will re-evaluate dose.
CIDP/MMN/MMN: significant improvement in disability and maintenance of improvement; IG at lowest effective dose/frequency.
LEMS: response to therapy evidenced by stability or improvement.
Many conditions: reauthorization intervals commonly 6 or 12 months depending on indication.

Step Therapy

Therapy trial requirements

Therapy trials and prior treatment documentation are required where indicated. Provide records showing trials and failures of standard first- and second-line therapies, or documentation of contraindication/intolerance when applicable.

Myasthenia gravis: documentation of trials of ≥2 standard therapies for 6‑month refractory authorization, or indication for 1‑month acute management.
Dermatomyositis/polymyositis: trials of corticosteroids and immunosuppressants unless contraindicated.
Stiff-person syndrome: trial and inadequate response to benzodiazepines and/or baclofen.
LEMS: trials of anticholinesterases and amifampridine with inadequate response or intolerance.

Step Therapy

Step therapy / prior treatment requirements

Step therapy/prior treatment requirements: many autoimmune, neurologic, and dermatologic indications require failure, intolerance, or contraindication to standard therapies before IG is authorized as chronic therapy. For acute or perioperative indications shorter authorizations may be granted without extensive prior trials.

Refractory myasthenia gravis: failed ≥2 standard therapies for 6‑month authorization.
Dermatomyositis/polymyositis: failed first- and second-line agents unless contraindicated for 3‑month initial authorization.
Autoimmune mucocutaneous blistering diseases: failed corticosteroids/immunosuppressants and pathology-confirmed diagnosis required.
Acute/exacerbation indications (e.g., GBS, Kawasaki, toxic shock): shorter authorizations (1 month) may be granted with supporting acute documentation.

Documentation Required

Required supporting records (general)

Required supporting records — submit copies of relevant laboratory reports, diagnostic test results, and clinical records to support the diagnosis and prior treatment history. Lack of required documentation is a common reason for denial.

Laboratory reports: serum IgG, IgA, IgM, IgG subclasses, and pre-treatment IgG levels where applicable.
Diagnostic studies: electrodiagnostic studies (EMG/NCS) for CIDP/MMN/MMN/LEMS, neurophysiology for LEMS, antibody testing (e.g., anti-GAD, anti‑P/Q VGCC).
Clinical records: documentation of standard treatments tried and failed, history of recurrent infections, bleeding risk factors for ITP, and operative plans for pre‑op use.

Documentation Required

Required supporting documentation (diagnostic confirmation examples)

Required supporting documentation — examples of diagnostic confirmation and condition-specific evidence to include with the request.

Primary immunodeficiency: genetic/molecular testing when applicable, lymphocyte subset enumeration by flow cytometry, impaired pneumococcal vaccine response (see Appendix A).
CIDP/MMN/MMN: pre‑treatment EMG or NCS confirming diagnosis.
Autoimmune blistering disease: biopsy and pathology report confirming diagnosis.

Documentation Required

Documentation requirements — IgG levels and laboratory evidence

Documentation requirements — specific laboratory evidence and monitoring to support initiation and continuation of IG therapy.

IgG levels: pretreatment serum IgG required for many indications (thresholds vary: e.g., <200 mg/dL for SCID, <500 mg/dL for CVID/CLL, <400 mg/dL in several transplant/CAR‑T/HIV pediatric settings).
IgG troughs: for members continuing IG, provide IgG trough level monitoring at least yearly; include recent trough values.
Other labs/tests: IgG subclasses, lymphocyte subsets, specific antibody testing, platelet counts for ITP, and parvovirus B19 testing for PRCA.

Documentation Required

Supportive documentation — pneumococcal antibody response and appendix notes

Supportive documentation — include pneumococcal antibody response results and clinical appendices as noted. Failure to document impaired vaccine response or other supportive tests may result in denial.

Pneumococcal polysaccharide vaccine response (post‑vaccination Streptococcus pneumoniae antibody titers) for impaired antibody response per Appendix A.
Appendix A notes: impaired antibody response criteria apply to age ≥2 years; not established for children <2 years; excludes hospital‑initiated therapy.
Appendix B: provide examples of bleeding risk factors when requesting ITP therapy for high‑risk patients.

Denial Risk

Risk factors for denial (missing documentation, lack of prior therapy trials)

Risk factors for denial: incomplete or missing documentation, lack of required prior therapy trials where step therapy is required, absence of diagnostic confirmation, missing laboratory thresholds (e.g., pretreatment IgG), or failure to meet reauthorization criteria.

Missing pretreatment or recent IgG levels or immunologic testing.
No documentation of trials and failures of standard therapies when required.
Lack of diagnostic confirmation (e.g., no EMG/NCS for CIDP, no biopsy for autoimmune blistering disease).
Failure to demonstrate response or meet reauthorization criteria for continuation of therapy.

Denial Risk

Continuation authorization risk

Continuation authorization risk: reauthorization will be denied if the member does not meet the reauthorization criteria listed for their condition (section III) or if required monitoring (e.g., IgG troughs, clinical response documentation) is not provided.

Conditions with explicit reauthorization criteria (e.g., primary immunodeficiency, CIDP, ITP, LEMS) must meet those criteria for continuation.
If reauthorization documentation is incomplete or does not show improvement/stability, requests will be denied.
For conditions without specific reauthorization language, members must still meet initial criteria to continue therapy.

Authorization implicationRequired documentation for initial authorization (6 months)

Diagnostic confirmation for Stiff-person Syndrome

Stiff-person syndrome diagnostic confirmationPositive anti-glutamic acid decarboxylase (GAD) antibody testing

Prior therapy requirementInadequate response to first-line treatment (benzodiazepines and/or baclofen) is required

Authorization implicationDocumentation of anti-GAD testing required for 6-month authorization

Autoimmune mucocutaneous blistering disease confirmation

Blistering disease diagnostic standardDiagnosis proven by biopsy and confirmed by pathology report

Clinical severity requirementCondition must be rapidly progressing, extensive, or debilitating

Prior therapy requirementFailure or significant complications from standard treatments (corticosteroids, immunosuppressives)

Impaired antibody response to pneumococcal polysaccharide vaccine (age ≥2)

Age requirement for impaired pneumococcal vaccine responseAge ≥ 2 years

Demonstration requiredImpaired antibody response demonstrated to pneumococcal polysaccharide vaccine

ExclusionsCriteria not established for children < 2 years and excludes therapy initiated in the hospital setting

Impaired antibody response to pneumococcal polysaccharide vaccine — restated

Restated impaired vaccine-response criterionFor age ≥2 years: impaired antibody response demonstrated to pneumococcal polysaccharide vaccine

Not established forChildren less than 2 years of age

Hospital initiation exclusionTherapy initiated in the hospital setting is excluded from this criterion

Risk factors for bleeding (appendix B examples)

Example: anticipated procedural blood lossUndergoing a medical or dental procedure where blood loss is anticipated

Comorbidities increasing bleeding riskComorbidity examples: peptic ulcer disease, hypertension

Other risk factorsMandated anticoagulation therapy or profession/lifestyle predisposing to trauma (e.g., construction worker, fireman, professional athlete)